We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4527:TSERohto Pharmaceutical Co., Ltd. Analysis

Data as of 2026-03-14 - not real-time

NT$42.10

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Kuen Ling Machinery trades at TWD 42.1, comfortably above its 20‑day (41.28), 50‑day (40.68) and 200‑day (41.03) moving averages, while the RSI sits at 61 and the MACD line is bullish, suggesting short‑term momentum remains intact. Valuation metrics are compelling: the stock’s PE of 12.5 is far below the industry average of 33.7 and the DCF‑derived fair value of 62.26 points to a roughly 30% upside potential. Dividend yield is exceptionally high at 7.6%, though the payout ratio approaches 95%, raising questions about sustainability if earnings continue to fall. Revenue has contracted sharply (‑30% YoY), yet the balance sheet is strong with a low debt‑to‑equity of 15%, ample cash (TWD 678 m) and robust free cash flow (TWD 319 m). Volatility over the past 30 days is moderate at 14.9% and beta is low (0.39), indicating limited market‑wide risk, while volume is rising, supporting liquidity. Overall, the stock appears undervalued with solid cash generation, but the steep revenue decline and aggressive dividend policy inject medium‑term uncertainty.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above key moving averages and bullish MACD
  • High dividend yield but near‑maximum payout ratio
  • Increasing trading volume supporting liquidity

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap vs DCF fair value
  • Strong cash flow and low leverage
  • Attractive dividend yield relative to peers

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue contraction raises growth concerns
  • Undervalued multiples and low beta suggest defensive profile
  • Potential upside if turnaround or dividend policy adjusts

Key Metrics & Analysis

Financial Health

Revenue Growth-30.30%
Profit Margin6.77%
P/E Ratio12.5
ROE10.90%
ROA3.96%
Debt/Equity15.42
P/B Ratio2.0
Op. Cash FlowNT$447.5M
Free Cash FlowNT$318.5M
Industry P/E33.7

Technical Analysis

TrendNeutral
RSI61.1
SupportNT$40.35
ResistanceNT$42.85
MA 20NT$41.28
MA 50NT$40.68
MA 200NT$41.03
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueNT$62.26
GradeUndervalued
TypeValue
Dividend Yield7.60%

Risk Assessment

Beta0.39
Volatility14.92%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.